Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic kidney disease with Type 2 diabetes

Patient must have a diagnosis of chronic kidney disease, defined as abnormalities of at least one of: (i) kidney structure, (ii) kidney function, present for at least 3 months, prior to initiating treatment with this drug; AND

Patient must not have known significant non-diabetic renal disease, prior to initiating treatment with this drug; AND

Patient must have an estimated glomerular filtration rate of 25 mL/min/1.73 m2 or greater, prior to initiating treatment with this drug; AND

Patient must have a urinary albumin-to-creatinine ratio of 200 mg/g (22.6 mg/mmol) or greater, prior to initiating treatment with this drug; AND

Patient must discontinue treatment with this drug prior to initiating renal replacement therapy, defined as dialysis or kidney transplant; AND

Patient must be stabilised, for at least 4 weeks, on either: (i) an ACE inhibitor or (ii) an angiotensin II receptor antagonist, unless medically contraindicated, prior to initiation of combination therapy with this drug; AND

The treatment must be in combination with an SGLT2i unless medically contraindicated or intolerant; AND

Patient must not be receiving treatment with another selective nonsteroidal mineralocorticoid receptor antagonist, a renin inhibitor or a potassium-sparing diuretic; AND

Patient must not have established heart failure with reduced ejection fraction with an indication for treatment with a mineralocorticoid receptor antagonist.